GLP-1 Side Effects: What 410,000 Reddit Posts Reveal About Real-World Experience

When researchers at the University of Pennsylvania wanted to understand what GLP-1 medications actually feel like for the people taking them, they did not run another clinical trial. They read Reddit.¹

The result, published in Nature Health in April 2026, is one of the largest studies of real-world GLP-1 side effects ever conducted. The dataset: 410,198 posts mentioning semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), written by 67,008 users who self-reported taking these medications, collected over six years from May 2019 through June 2025.

The headline finding: 43.5% of those users posted about at least one side effect. And the patterns of what they report, how they describe it, and what they search for afterward tell a story that clinical trial data alone cannot.

For anyone managing GLP-1 side effects alongside fiber intake, this study provides something rare: a window into what real users actually experience, struggle with, and ask for help with, at scale. The signals it surfaces also map directly onto the European fiber gap, where adults already eat well below recommended levels before any medication enters the picture.

What did the study actually measure?

Before diving into the findings, it is worth understanding what this study is and what it is not. This matters for interpreting everything that follows.

The researchers used natural language processing to identify Reddit users who self-reported taking semaglutide or tirzepatide across multiple GLP-1-related subreddits (r/Ozempic, r/WegovyWeightLoss, r/Mounjaro, r/antiobesitymed, r/tirzepatide, among others). They then analyzed posts for mentions of side effects and categorized them.

This is observational, self-reported data from a social media platform, not a controlled clinical trial. The authors are explicit about the limitations:

• Reddit skews younger, male, and US-based. The population is not representative of the global GLP-1 user base, which includes older patients, more women, and users across Europe and other regions.
• Self-report bias. People who experience side effects may be more likely to post about them than people who do not. The 43.5% figure is not a prevalence estimate for the general GLP-1 population.
• No dose verification. The study cannot confirm what dose users were actually taking, whether they were titrating, or whether they were using the medication as prescribed.

The authors describe their results as “hypothesis-generating signals,” not definitive answers. That framing is correct and important.

What makes the study valuable despite these caveats is its scale. Clinical trials for semaglutide and tirzepatide typically enroll hundreds to a few thousand participants over 12 to 72 weeks. This study captured over 400,000 posts from 67,000 users over six years. It surfaces patterns that controlled trials, by design, are not built to detect.

The side effect hierarchy: what users actually report

Among the 43.5% of users who posted about side effects, the top five complaints were:¹

The nausea finding is unsurprising: it is the most widely reported GLP-1 side effect in clinical trials as well. But the rest of the ranking challenges what trial data emphasizes.

Fatigue at #2 is the standout. In clinical trials, fatigue rarely appears as a prominent adverse event. On Reddit, it is the second most commonly discussed complaint, reported by nearly one in six users who mention side effects. This gap between trial reporting and real-world experience is exactly the kind of signal the study was designed to surface.

Constipation at #4 confirms what GLP-1 communities have been saying for years. In clinical trials, constipation rates range from roughly 5% on diabetes-indication doses (semaglutide for type 2 diabetes) to 16-24% on weight-management doses (tirzepatide as Zepbound). The Reddit figure of 15.3% falls within that range, but the raw number understates how much it dominates the conversation. Constipation is the most actionable GI complaint because, unlike nausea, it does not tend to resolve on its own with continued use.

The side effects clinical trials may be undercounting

Beyond the top five, the study identified several categories of side effects that appear in Reddit discussions at rates higher than clinical trials suggest:

Reproductive symptoms. Menstrual irregularities appeared in approximately 4% of the total sample, a figure that rises substantially when filtered to female users only. Clinical trials have not systematically tracked menstrual changes as an endpoint.

Psychiatric symptoms. Anxiety, insomnia, and depression were mentioned by roughly 13% of users who reported side effects. These symptoms are difficult to attribute directly to the medication (they may be related to rapid weight changes, dietary shifts, or pre-existing conditions), but their frequency in user reports suggests they deserve more systematic study.

Temperature-related complaints. Chills and hot flashes appeared as a recurring theme, another category not typically tracked in GLP-1 clinical trials.

None of these findings prove that GLP-1 medications cause these symptoms. The study design cannot establish causation. But the scale and consistency of the reports is a signal that clinical research has not yet fully addressed.

Why constipation is the fiber problem in disguise

Constipation on GLP-1 medications is not a single mechanism. It is three mechanisms compounding each other, and all three involve fiber.

Delayed gastric emptying. GLP-1 receptor agonists slow the rate at which food moves from the stomach into the small intestine. This is intentional: it is how the drugs suppress appetite and moderate blood sugar. But slower transit at the top cascades through the entire digestive system. Food, and eventually stool, moves more slowly through the colon. More water is reabsorbed. The result is harder, drier stool that is more difficult to pass.²

Reduced food volume. GLP-1 medications are effective appetite suppressants. Eating less means less bulk moving through the intestines. Less bulk means slower transit and weaker peristaltic signaling. For fiber specifically, lower total food intake almost always means lower fiber intake, because fiber comes from food.

Reduced fluid intake. Appetite suppression often extends to thirst. Users drinking less water compound the problem: fiber needs adequate hydration to function. Without it, fiber can actually make constipation worse by absorbing water from the gut.

This creates a catch-22 that GLP-1 communities describe repeatedly. Users need more fiber to maintain bowel function, but the medication makes them eat less (reducing fiber from food), feel less thirsty (reducing the water fiber needs), and slows their gut (meaning any gas from fiber fermentation stays trapped longer, causing bloating). Users who try to add fiber and experience bloating often quit, concluding that fiber “doesn’t work” or “makes it worse.”

The adjustment period can take up to 47 days. Symptoms often intensify at dose escalations, restarting the cycle.

What GLP-1 users actually search for (and what they get wrong)

The Reddit data, combined with clinical synthesis of community discussions, reveals a consistent set of questions and misconceptions:

“What fiber supplement should I take on Ozempic?”

This is one of the highest-frequency questions in GLP-1 subreddits. Users want a specific recommendation, not generic “eat more fiber” advice. The answer is more nuanced than a single product name.

Different fiber types have different mechanisms, and those mechanisms interact differently with the slowed GLP-1 gut:

• Psyllium husk (Metamucil and equivalents) forms a viscous gel that adds bulk and softens stool. It is the American Gastroenterological Association’s first-line recommendation for chronic constipation. It ferments relatively slowly, producing less gas than some alternatives.
• Methylcellulose (Citrucel) is a synthetic fiber with very low fermentation, meaning minimal gas production. It is a good option for users who react to other fibers with bloating.
• Inulin and chicory root are highly fermentable prebiotic fibers. They feed beneficial gut bacteria, but their fermentation produces more gas. In the context of slowed gastric emptying, that gas stays trapped longer, which is why GLP-1 users frequently report that protein bars and shakes containing chicory root cause severe bloating.
• Wheat bran adds insoluble bulk but can also worsen bloating in the GLP-1 context.

No single fiber type is universally “best.” The right choice depends on individual tolerance, the severity of symptoms, and whether the primary goal is constipation relief, prebiotic support, or both. For a detailed comparison of psyllium husk and chicory inulin for GLP-1 users, including FODMAP considerations, see our chicory inulin vs. psyllium guide. The consistent clinical advice is to start with a low dose (roughly 5g per day) and increase gradually, adding about 5g per week, while increasing water intake simultaneously.³

”Does fiber interfere with my Ozempic?”

No. Injectable GLP-1 medications (semaglutide as Ozempic or Wegovy, tirzepatide as Mounjaro or Zepbound) are absorbed subcutaneously, not through the digestive tract. Fiber in the gut does not affect their absorption or mechanism of action.

The exception is oral GLP-1 formulations. Oral semaglutide (Rybelsus) is taken on an empty stomach with a small amount of water, and other substances in the stomach can interfere with absorption. Fiber supplements should be separated from oral semaglutide by at least two hours.

”Is psyllium husk ‘nature’s Ozempic’?”

This narrative went viral on TikTok and Reddit, with users calling psyllium the “poor man’s Ozempic.” It is clinically inaccurate. There are no head-to-head studies comparing psyllium husk to any GLP-1 medication, and GLP-1 receptor agonists produce significantly greater weight loss through a fundamentally different mechanism (hormonal appetite regulation vs. mechanical bulk in the gut).

Psyllium is a useful tool for managing constipation and supporting gut health alongside GLP-1 therapy. It is not a replacement for the medication itself. Framing it as one risks encouraging people to abandon effective treatment.

”I’m only eating 800 calories. How do I get enough fiber?”

This is one of the most practical questions and one of the least well-answered online. The standard fiber recommendations still apply: EFSA recommends 25g per day, Germany’s DGE recommends 30g per day. But for someone eating 800 to 1,200 calories, reaching those targets through food alone is extremely difficult.

A fiber supplement becomes a practical necessity in this context, not a luxury. The key is choosing one that does not exacerbate GI symptoms and introducing it gradually.

”Sulfur burps on Ozempic: what is causing them?”

This is a high-visibility complaint in GLP-1 communities. The burps are caused by hydrogen sulfide (H2S) production during fermentation in the gut. Foods and supplements containing inulin (including protein bars with chicory root), asparagus, and certain cruciferous vegetables are commonly identified triggers. The slowed gastric emptying on GLP-1s means fermentation gases are released more slowly and can build up, making the sulfur burps more noticeable and persistent.

The bigger picture: what clinical trials are not designed to see

The Nature Health study is not a replacement for clinical trial data. It cannot establish causation, confirm dosages, or control for confounders. Its population is not representative.

But it reveals something clinical trials structurally cannot: the lived texture of taking these medications. The frustration of constipation that worsens at every dose increase. The confusion about which fiber to take. The bloating trap where users add fiber, feel worse, and quit. The fatigue that no one warned them about. The anxiety about side effects that compounds the anxiety they are already managing.

Clinical trials measure whether a drug works and whether it is safe. They are less equipped to measure whether a drug is liveable, day after day, for the years that chronic weight management requires. That is the gap this study starts to fill.

For the 15.3% of users discussing constipation, and likely many more who experience it without posting, the practical implication is straightforward: fiber is not optional on GLP-1 therapy. It is a structural necessity created by the drug’s own mechanism. The question is not whether to supplement fiber, but which type, how much, and how to introduce it without making things worse.

The answer, based on both the clinical evidence and the hard-won experience of thousands of Reddit users, is the same: start low, go slow, drink more water than you think you need, and if one fiber type causes problems, try a different one before giving up entirely.